In clinical practice, clinicians may prefer to select chemotherapy schemes other than platinum containing chemotherapy for patients with ERCC1 polymorphism rs11615 TT genotype, such as early use of PARP inhibitors and anti-angiogenesis, especially in ovarian cancer. Here, ERCC1 is linked to ovarian carcinoma.